时间标签：数据日期 2026-11-01 · 生成时间 2026-11-01 05:30（Asia/Shanghai）｜ 检索窗口 PubMed edat 2026/10/31–2026/11/01 ｜ 情报发生日期 2026-11-01
证据级别：摘要级。本条依据 PubMed 结构化摘要与元数据撰写，付费墙全文未获取、未逐节核验，本站未做任何数值推算补全。
研究问题
This study aims to identify distinct clinical and biological subtypes of Mild Cognitive Impairment (MCI) and their progression stages using a data-driven multimodal approach, aimed at improving the stratification and prediction of…
方法
We applied the Subtype and Stage Inference (SuStaIn) algorithm to a multimodal dataset from the Alzheimer's Disease Neuroimaging Initiative (ADNI) to identify distinct MCI subtypes and their progression stages on 558 patients classified as…
核心结论
We delimited four subtypes, which two exhibited higher risk for conversion to AD.
局限
Thus, applying SuStaIn to multidomain data successfully disentangles the phenotypic heterogeneity of MCI.
对本项目的价值
临床前机制证据，需评估物种外推与剂量可行性：神经退行是长寿干预最难攻的终点，本文提供机制或生物标志物层面的抓手。 ｜ 价值分 1.0/5（★☆☆☆☆）
全文来源
未取到全文 → 本卡为摘要级解读，未核验全文
原文题录
- 英文标题：Stratifying heterogeneity in mild cognitive impairment: A multimodal subtype and stage inference approach.
- 期刊与标识：Neurobiology of aging · PMID 42956622 · DOI 10.1016/j.neurobiolaging.2026.10.006
A 级证据分级：A 级（同行评议人体研究）
本文属人体研究证据，但需注意：观察性或小样本干预的结论不等于已证实临床获益；效应量与长期安全性仍需更大规模、更长随访的试验验证。
关于本文的文献来源：本站依据 IMA 知识库「五刊监控·深度文献卡片」（SOP §4.2 摘要级）撰写，依据期刊公开摘要与 PubMed 元数据；付费墙全文未获取之处已标注「待补全文」，未做任何数值推算补全。